Hubbry Logo
AnuriaAnuriaMain
Open search
Anuria
Community hub
Anuria
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Anuria
Anuria
Anuria
View on Wikipedia
from Wikipedia
Anuria
Other namesAnuresis
SpecialtyNephrology

Anuria is nonpassage of urine,[1] in practice is defined as passage of less than 100[2] milliliters of urine in a day.[3] Anuria is often caused by failure in the function of kidneys. It may also occur because of some severe obstruction like kidney stones or tumours. It may occur with end stage kidney disease. It is a more extreme reduction than oliguria (hypouresis), with 100 mL/day being the conventional (albeit slightly arbitrary) cutoff point between the two.

Signs and symptoms

[edit]

Anuria itself is a symptom, not a disease. It is often associated with other symptoms of kidney failure, such as lack of appetite, weakness, nausea and vomiting. These are mostly the result of buildup of toxins in the blood which would normally be removed by healthy kidneys.

Causes

[edit]

Failure of kidney function, which can have multiple causes including medications or toxins (e.g., antifreeze, cephalosporins, ACEIs); diabetes; high blood pressure. Stones or tumours in the urinary tract can also cause it by creating an obstruction to urinary flow. High blood calcium, oxalate, or uric acid, can contribute to the risk of stone formation. In males, an enlarged prostate gland is a common cause of obstructive anuria.

Acute anuria, where the decline in urine production occurs quickly, is usually a sign of obstruction or acute kidney failure. Acute kidney failure can be caused by factors not related to the kidney, such as heart failure, mercury poisoning, infection, and other conditions that cause the kidney to be deprived of blood flow.

Treatment

[edit]

Treatment is dependent on the underlying cause of this symptom. The most easily treatable cause is obstruction of urine flow, which is often solved by insertion of a urinary catheter into the urinary bladder.

Mannitol is a medicine that is used to increase the amount of water removed from the blood and thus improve the blood flow to the kidneys. However, mannitol is contraindicated in anuria secondary to renal disease, severe dehydration, intracranial bleeding (except during craniotomy), severe pulmonary congestion, or pulmonary edema.

Dextrose and dobutamine are both used to increase blood flow to the kidney and act within 30 to 60 minutes.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Anuria

View on Grokipedia
from Grokipedia
Anuria is a critical medical condition defined as a severe reduction or complete cessation of production by the , typically less than 100 milliliters per day in adults, contrasting with the normal output of over 500 milliliters daily. It is the most extreme manifestation of and signals profound impairment in renal function, often arising suddenly and requiring immediate intervention to prevent life-threatening complications such as imbalances, overload, or permanent damage. As a symptom rather than a standalone , anuria demands urgent to identify and address the underlying , which can span prerenal, intrinsic renal, or postrenal mechanisms. The causes of anuria are broadly categorized into three types based on the site of dysfunction. Prerenal anuria results from reduced blood flow to the kidneys, commonly due to severe , significant blood loss, , or , leading to inadequate and glomerular . Intrinsic renal anuria stems from direct damage to kidney tissue, such as from toxins (e.g., certain medications or contrast dyes), ischemic injury, or inflammatory conditions like acute . Postrenal anuria occurs from obstruction of urine outflow, often caused by bilateral ureteral stones, tumors, or prostate enlargement in males, preventing from exiting the body. Systemic factors like uncontrolled or can exacerbate these risks by contributing to progression toward anuric states. Symptoms of anuria extend beyond absent urination and include fluid retention manifesting as swelling () in the legs, ankles, or face; ; from pulmonary congestion; ; confusion due to ; and potential blood in any scant urine produced. Diagnosis involves a thorough history, , and laboratory tests, including measurement of urine output, (BUN), creatinine levels, and to assess for casts or infection; imaging such as or CT scans may identify obstructions, while is reserved for unclear intrinsic causes. Treatment is cause-specific and emergent: prerenal cases may respond to intravenous fluids and vasopressors, postrenal obstruction requires catheterization or surgical relief, and severe intrinsic damage often necessitates dialysis to support renal replacement until recovery or further options like transplantation. Early intervention is vital, as untreated anuria carries high mortality, particularly in the context of where it correlates with adverse outcomes.

Overview

Definition

Anuria is defined as a urinary output of less than 100 per day in adults. The term originates from the Greek "an-" (without) and "ouria" (), reflecting the complete or near-complete absence of production; it was coined in medical Latin around 1838 and first appeared in literature during the early 19th century, amid emerging understandings of renal failure. This condition is distinguished from , which involves a reduced but measurable output of less than 400 mL per day, and from normal , typically ranging from 800 to 2000 mL per day in adults with adequate fluid intake. In pediatric populations, diagnostic thresholds are weight-based and adjusted for age; for instance, in neonates is defined as output below 1 mL/kg/hour, while anuria indicates near-complete absence after the initial 24 hours, accounting for their lower baseline production compared to adults. Clinically, anuria signifies profound renal dysfunction and frequently represents the terminal phase of (AKI), necessitating urgent evaluation to prevent life-threatening complications such as fluid overload and derangements.

Epidemiology

Anuria, defined as urine output less than 100 mL per day, represents a severe manifestation of (AKI) and occurs in a notable proportion of affected patients. Studies indicate that anuric AKI develops in approximately 21% of hospitalized patients with AKI requiring , with septic and postoperative etiologies being predominant causes. In (ICU) settings, where AKI incidence reaches 50-60%, the rate of anuria can be higher due to the severity of illness, though specific figures vary by population and study design. Globally, AKI, of which anuria is a severe form, affects an estimated 13 million people annually as of recent analyses ( data, with ongoing increases noted through ). Demographic risk factors significantly influence anuria prevalence. It is more frequent among elderly individuals over 65 years, where AKI incidence rises sharply due to reduced renal reserve and . Males face elevated risk from obstructive causes, particularly leading to post-renal anuria. Comorbidities such as further amplify susceptibility to severe AKI, including progression to anuria. Geographic variations highlight disparities in anuria burden, often tied to infectious and resource-limited contexts. In low- and middle-income regions like , infectious etiologies such as severe contribute substantially, with AKI complicating up to 60% of severe malaria cases and anuria emerging in advanced stages. This contrasts with higher-income settings, where iatrogenic and cardiovascular causes predominate. Recent trends (as of 2025) underscore a rising global incidence of AKI, including anuria-linked cases, paralleling the increasing prevalence of (CKD), driven by aging populations and rising rates.

Pathophysiology

Mechanisms

Anuria arises primarily from a severe impairment in the (GFR), typically falling below 10 mL/min, which effectively halts formation by disrupting the balance between filtration and processes. This reduction occurs through mechanisms such as tubular backleak, where damaged tubular epithelium permits the of filtered fluid back into the , and tubular obstruction, caused by sloughed cellular debris and casts that block luminal flow, preventing progression to the . In (ATN), a common pathway to anuria, these factors combine to minimize net output to less than 100 mL per day. Renal blood flow dynamics play a central role, as reduced perfusion pressure—often due to hypovolemia, hypotension, or systemic vasoconstriction—leads to ischemic damage in the nephrons, further depressing GFR. The GFR can be approximated by the Starling equation for ultrafiltration across the glomerular capillary membrane: GFR=Kf×(PGC−PBS−πGC)\text{GFR} = K_f \times (P_{GC} - P_{BS} - \pi_{GC}) where KfK_f is the filtration coefficient (reflecting glomerular permeability and surface area), PGCP_{GC} is the glomerular capillary hydrostatic pressure (driving filtration), PBSP_{BS} is the Bowman's space hydrostatic pressure (opposing filtration), and πGC\pi_{GC} is the glomerular capillary oncotic pressure (opposing filtration due to plasma proteins). This equation derives from the net filtration pressure, balancing hydrostatic and oncotic forces along the glomerular capillaries; a decrease in PGCP_{GC} from low renal perfusion directly lowers GFR, while increases in PBSP_{BS} (e.g., from tubular obstruction) or πGC\pi_{GC} (from hemoconcentration) exacerbate the reduction. Prolonged hypoperfusion triggers ischemic injury, particularly in the vulnerable proximal tubules and thick ascending limb, perpetuating the cycle of low GFR. Tubular and interstitial factors contribute significantly, with and compressing renal tubules and impairing filtrate flow. In , necrotic tubular cells release damage-associated molecular patterns, inciting necroinflammation that leads to interstitial and , which mechanically obstructs tubules and reduces the effective surface. Vasoconstrictors such as angiotensin II, activated via the renin-angiotensin-aldosterone system in response to hypoperfusion, preferentially constrict the initially but, in severe cases, cause widespread renal , worsening ischemic damage and sustaining low renal blood flow. Systemic contributors, including fluid depletion or overload, alter forces across the glomerular membrane, tipping the balance against . decreases effective circulating volume, reducing PGCP_{GC} and thus GFR, while fluid overload—such as in congestive —can elevate venous pressure, indirectly increasing PBSP_{BS} and oncotic forces through hemodilution imbalances. These systemic perturbations amplify local renal mechanisms, leading to the profound suppression of production characteristic of anuria.

Relation to Acute Kidney Injury

Anuria represents the most severe manifestation of (AKI), classified as stage 3 according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, where it is defined as complete cessation of output for 12 hours or more, or less than 0.3 mL/kg/hour for 24 hours or more, often accompanied by a serum increase of baseline or initiation of . This staging underscores anuria's role as a critical endpoint in AKI progression, signaling profound impairment and heightened risk of complications. The evolution of AKI staging frameworks has positioned anuria within standardized diagnostic paradigms, beginning with the criteria in 2004, which categorized "failure" by urine output less than 0.3 mL/kg/hour for 24 hours or anuria for 12 hours, followed by the Acute Kidney Injury Network (AKIN) modifications in 2007 that refined thresholds for earlier detection. The KDIGO guidelines, published in 2012, integrated these into a unified three-stage system, emphasizing urine output criteria for staging while incorporating serum creatinine changes, with ongoing discussions since 2020 highlighting the integration of biomarkers for refined progression assessment. AKI progression typically advances from stage 1 (mild with rise ≥0.3 mg/dL) through stage 2 ( <0.5 mL/kg/hour) to stage 3 (), driven by escalating tubular damage and hemodynamic instability, where early biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) can predict transition to severe stages with an area under the curve of 0.75–0.86 for dialysis-requiring AKI. often emerges in the oliguric or anuric phase following onset, reflecting advanced injury. Early intervention within 24–48 hours of anuria onset offers potential for reversibility, with durations exceeding 24 hours associated with incomplete renal recovery in up to 85% of cases based on sensitivity analyses. However, 20–30% of severe AKI episodes, including those with anuria, transition to chronic kidney disease (CKD), particularly when recovery is delayed or incomplete, as evidenced by long-term cohort studies showing CKD development in 21–29% of survivors.

Clinical Presentation

Signs and Symptoms

The primary sign of anuria is the complete or near-complete absence of urine production, typically defined as less than 100 mL per day, leading patients to report no voiding for at least 12 hours or more. This lack of urination often prompts urgent medical attention, as individuals may notice reduced or absent bathroom visits and potential discomfort from a distended bladder if obstruction is involved. As anuria persists due to underlying renal impairment, uremic symptoms emerge from the accumulation of toxins and waste products in the blood, including nausea, vomiting, fatigue, and pruritus (itching). In advanced cases, patients may experience a metallic taste in the mouth (dysgeusia) and mental changes such as confusion or lethargy, reflecting uremic encephalopathy. Fluid balance disturbances are prominent, manifesting as edema in the extremities (such as legs, ankles, and feet), hypertension from volume overload, and shortness of breath due to pulmonary congestion or edema. Symptoms generally escalate rapidly within 24 to 72 hours of onset, with generalized weakness becoming a common complaint among affected patients as toxin buildup and fluid retention worsen.

Differential Diagnosis

Differentiating true anuria, characterized by negligible urine production from the kidneys (less than 100 mL per day), from mimicking conditions is essential to guide appropriate management and avoid misdiagnosis. Key differentials include severe oliguria, urinary retention, and factitious anuria, each requiring distinct diagnostic approaches to confirm the underlying mechanism. Severe oliguria, defined as urine output below 0.5 mL/kg/hour for at least 6-12 hours, often represents an earlier stage or milder form of renal hypoperfusion that may progress to anuria if untreated, but it differs in that some urine production persists. Urinary retention, particularly acute cases due to benign prostatic hyperplasia (BPH) in older men or urethral strictures, presents as apparent anuria because urine is produced but cannot be voided, leading to bladder distension; this accounts for a notable proportion of suspected anuria presentations, with postrenal obstruction implicated in 5-10% of acute kidney injury cases overall. Factitious anuria, though uncommon, arises from intentional behaviors such as surreptitious clamping of indwelling catheters in hospitalized patients, often linked to underlying factitious disorder, and can mimic renal failure until device inspection reveals the issue. Rare mimics encompass prerenal azotemia without complete cessation of urine output, where hypovolemia or reduced renal perfusion causes reversible oliguria that responds to fluid resuscitation, thereby distinguishing it from intrinsic renal damage leading to true anuria. Endocrine conditions like central or nephrogenic diabetes insipidus, conversely, feature excessive polyuria due to impaired urine concentration, serving as a stark contrast to anuria and prompting evaluation for water balance disorders in atypical presentations. Diagnostic clues are critical for resolution: a palpable, distended bladder on abdominal examination strongly suggests urinary retention over true anuria, where the bladder remains non-palpable due to absent production. Additionally, a positive response to a fluid challenge—manifesting as increased urine output—supports prerenal etiologies, whereas lack of response points toward intrinsic or postrenal causes. In cases of suspected retention-related anuria, per recent reviews, underscoring the need for prompt bladder assessment to prevent complications like overflow incontinence. Symptoms such as lower abdominal discomfort or edema may overlap but require differentiation based on these physical findings.

Etiology

Pre-renal Causes

Pre-renal causes of arise from conditions that impair renal perfusion upstream of the kidney, leading to reduced glomerular filtration rate (GFR) without intrinsic renal parenchymal damage. These etiologies account for a substantial proportion of acute kidney injury (AKI) cases that progress to anuria, emphasizing the importance of prompt volume resuscitation and addressing the underlying hypoperfusion. is a primary pre-renal cause, resulting from significant fluid losses that decrease effective circulating blood volume and renal blood flow. Common triggers include dehydration due to prolonged vomiting, diarrhea, or inadequate intake; acute hemorrhage from trauma or gastrointestinal bleeding; and severe burns causing plasma extravasation and third-space fluid shifts. In community-acquired AKI, hypovolemia contributes to 40-70% of cases, often manifesting as oliguria or anuria when renal autoregulation fails to compensate for the perfusion deficit. Cardiorenal syndrome, particularly type 1, occurs when acute heart failure diminishes cardiac output, thereby reducing renal perfusion pressure and GFR. This hemodynamic compromise is exacerbated in patients with severely reduced left ventricular function, such as ejection fraction below 30%, where forward failure leads to systemic underfilling and venous congestion, promoting anuric states through sustained hypoperfusion. Certain medications can induce pre-renal anuria by altering renal arteriolar tone in vulnerable individuals, such as those with baseline volume depletion or chronic conditions. Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis, causing unopposed afferent arteriolar vasoconstriction and a drop in GFR. Angiotensin-converting enzyme (ACE) inhibitors block efferent arteriolar vasoconstriction via the renin-angiotensin system, further compromising intraglomerular pressure. In elderly patients, the incidence of NSAID- or ACE inhibitor-associated pre-renal AKI ranges from 5-13%, with higher risks in those over 65 years due to diminished renal reserve. Sepsis represents another critical pre-renal mechanism, where systemic inflammatory responses trigger widespread vasodilation, capillary leak, and distributive shock, culminating in renal hypoperfusion. In septic shock, these effects are pronounced, with relative hypovolemia compounding the maldistribution of blood flow away from the kidneys. Data from recent studies indicate that severe AKI, including progression to anuria, occurs in 25-50% of septic shock cases, highlighting sepsis as a major driver of pre-renal anuria in intensive care settings.

Intrinsic Renal and Post-renal Causes

Intrinsic renal causes of anuria stem from direct damage to the kidney's structural components, such as the tubules, glomeruli, or interstitium, leading to impaired urine production. Acute tubular necrosis (ATN) represents the most prevalent intrinsic etiology, accounting for approximately 50% of hospital-acquired acute kidney injury (AKI) cases that manifest as anuria or severe oliguria. ATN arises primarily from ischemic injury due to prolonged hypoperfusion or nephrotoxic insults, including aminoglycoside antibiotics and iodinated contrast agents, which disrupt tubular epithelial cell integrity and cause intratubular obstruction. COVID-19-associated AKI, observed in studies up to 2025, contributes via ischemic and inflammatory mechanisms, with incidence approximately 25-50% in severe or ICU-admitted cases, and about 28% overall in critically ill patients. Glomerulonephritis, particularly rapidly progressive forms with crescent formation, also contributes to intrinsic anuria by inducing severe glomerular inflammation and extracapillary proliferation, which rapidly diminishes glomerular filtration and results in oliguria or anuria as an initial presentation of AKI. Crescents, formed by proliferating parietal epithelial cells and leukocytes in Bowman's space, are hallmark features in conditions like anti-glomerular basement membrane disease or ANCA-associated vasculitis, exacerbating renal parenchymal damage. Post-renal causes involve mechanical or functional obstruction of urine outflow distal to the kidneys, comprising 5-10% of all AKI cases and often presenting with abrupt anuria, especially when bilateral. Bilateral ureteral obstruction, for instance, can result from urolithiasis or retroperitoneal tumors, leading to back-pressure on the renal pelvis and tubules that halts filtration. In elderly males, benign prostatic hyperplasia (BPH) is the leading obstructive etiology, affecting up to 80% of men over 70 and causing bladder outlet obstruction that precipitates anuria in a substantial proportion of symptomatic cases through chronic urinary retention and secondary hydronephrosis. Certain conditions bridge intrinsic and post-renal mechanisms, such as crystal nephropathy induced by drugs like acyclovir, where precipitation of insoluble crystals in renal tubules causes intratubular obstruction and acute tubular injury, manifesting as AKI with reduced urine output within 24-48 hours of administration, particularly in dehydrated patients. Similarly, neurogenic bladder following spinal cord injury disrupts detrusor-sphincter coordination, promoting urinary stasis and high-pressure retention that can evolve into bilateral obstruction and AKI, including non-oliguric or anuric forms complicated by infection.

Diagnosis

Clinical Evaluation

The clinical evaluation of anuria begins with a thorough history and physical examination to identify potential causes and assess the urgency of intervention, as anuria—defined as urine output less than 100 mL per day—signals severe renal impairment requiring prompt assessment. History-taking focuses on recent changes in fluid balance, querying the patient's intake and output over the preceding 24 to 48 hours to establish the onset and pattern of anuria, which may differentiate acute from subacute processes. Medication history is critical, including recent use of nephrotoxic agents such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, or aminoglycosides, which can precipitate renal hypoperfusion or direct tubular injury. Inquiries into trauma, surgery, or hemorrhagic events help identify hypovolemia as a contributor, while symptoms like flank pain may suggest obstruction or infarction. Risk factors such as a history of diabetes mellitus, hypertension, or chronic kidney disease should be elicited, as they predispose to ischemic or toxic insults. The physical examination evaluates volume status and signs of underlying pathology, starting with vital signs to detect hypotension (systolic blood pressure below 90 mmHg), which indicates pre-renal hypovolemia, or fever suggestive of sepsis or infection-related anuria. Signs of dehydration, including dry mucous membranes, reduced skin turgor, and orthostatic hypotension upon standing, point to volume depletion, while peripheral edema or jugular venous distension may signal overload from cardiac or renal failure. Abdominal examination includes palpation for distension or a palpable bladder, indicating possible post-renal obstruction; if retention is suspected, bladder catheterization can confirm anuria by yielding little to no urine output. Simple assessments for volume status, such as measuring orthostatic vital sign changes (e.g., a drop in systolic blood pressure greater than 20 mmHg upon standing), aid in quantifying without advanced tools. In preoperative settings, tools like the STOP-Bang questionnaire can screen for as a risk factor for perioperative anuria due to hemodynamic instability. Uremic symptoms, such as fatigue or nausea, may emerge in prolonged anuria but are explored further in clinical presentation details.

Laboratory and Imaging Studies

Laboratory studies are essential for confirming anuria in the context of acute kidney injury (AKI) and differentiating its underlying causes. Serum creatinine levels typically rise significantly in anuria, with a diagnostic threshold for AKI including an increase of ≥0.3 mg/dL within 48 hours or ≥1.5 times the baseline value, often exceeding 2.5 mg/dL in severe cases associated with oliguria or anuria. The blood nitrogen (BUN) to creatinine ratio is a key indicator, with values >20:1 suggesting prerenal causes due to enhanced in hypoperfused states. imbalances are common, particularly exceeding 6 mEq/L, which arises from impaired renal excretion and requires urgent monitoring to prevent cardiac complications. Urinalysis provides critical insights into renal parenchymal involvement. In acute tubular necrosis (ATN), a frequent intrinsic cause of anuria, microscopic examination often reveals muddy brown granular casts and renal tubular epithelial cells, indicating tubular injury. The fractional excretion of sodium (FENa) is another valuable metric, with values <1% supporting prerenal etiology by reflecting intact tubular sodium reabsorption, whereas FENa >2% points to intrinsic renal damage. Emerging biomarkers enhance early detection of AKI leading to anuria. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) are detectable in urine or serum shortly after renal insult, preceding rises in creatinine and aiding in distinguishing structural injury from functional causes. Imaging modalities help identify structural abnormalities contributing to anuria. Renal ultrasound is the initial study of choice, particularly for detecting hydronephrosis indicative of postrenal obstruction, with high sensitivity for bilateral involvement causing anuria. Computed tomography (CT) is employed when ultrasound is inconclusive, offering detailed visualization of urolithiasis, tumors, or retroperitoneal processes obstructing urine flow. Renal Doppler ultrasound assesses vascular patency, identifying renal artery stenosis through elevated resistive indices or tardus-parvus waveforms in prerenal scenarios. In cases of unexplained intrinsic renal causes, may be indicated to establish a definitive , such as , with a diagnostic yield approaching 70% in suspected glomerular diseases.

Management

Supportive Care

Supportive care for patients with anuria primarily aims to maintain hemodynamic stability, correct life-threatening and acid-base disturbances, and minimize uremic complications while avoiding exacerbation of overload. This involves close collaboration with multidisciplinary teams, including nephrologists, to monitor and adjust interventions based on the patient's clinical status. Note that the cited KDIGO 2012 AKI guideline is undergoing updates as of 2023, with ongoing refinements in management strategies. Fluid management is critical in anuria to prevent and cardiac strain from , given the complete absence of output. Intravenous isotonic crystalloids, such as 0.9% saline, are administered judiciously at rates of 30-50 mL per hour to cover insensible losses and nutritional needs, with total daily intake typically limited to 500-800 mL plus any enteral or volume. monitoring or invasive hemodynamic assessment guides adjustments, targeting euvolemia; balanced crystalloids like lactated Ringer's may be preferred over normal saline to reduce risk. Diuretics are generally ineffective in true anuria but can be trialed if partial responsiveness is suspected. Electrolyte correction addresses common derangements in anuria, particularly , which can lead to cardiac arrhythmias. For serum potassium levels exceeding 6.5 mEq/L or with electrocardiographic changes, temporary measures include intravenous insulin with glucose infusion to shift intracellularly, alongside to stabilize cardiac membranes and protect against arrhythmias. -binding resins or beta-2 agonists may supplement these, with dietary restriction enforced; severe or refractory cases necessitate urgent . Other imbalances, such as or , are managed with phosphate binders or as needed to maintain serum levels within safe ranges. Nutritional support in anuric patients seeks to reduce uremic accumulation while meeting requirements without contributing to overload. A of less than 0.8 g/kg per day is recommended for non-dialyzed individuals to limit , with provision targeted at 20-30 kcal/kg per day via enteral routes when feasible to preserve . and intake are restricted, and if worsens with pH below 7.2, preparation for dialysis is prioritized to enable safer delivery. is reserved for intolerance to enteral feeding, with careful supplementation. Recent ESPEN guidelines (2024) align with these recommendations for AKI patients. Ongoing monitoring ensures timely detection of deterioration and guides supportive measures. A is placed to measure hourly urine output, confirming anuria (typically <100 mL per day) and assessing for any recovery. Daily body weights, charts, and track volume status, while serial laboratory assessments of electrolytes, , , and arterial blood gases detect imbalances early. Central venous or catheterization may be used in intensive care settings for precise fluid management.

Targeted Interventions

Targeted interventions for anuria focus on addressing the specific underlying to restore renal , alleviate tubular , or relieve obstruction, thereby promoting recovery of kidney function. In pre-renal anuria, caused by or reduced renal , initial involves prompt volume using balanced crystalloids such as lactated to correct and improve (GFR). Additionally, discontinuation of offending medications, particularly inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), is essential to mitigate their vasoconstrictive effects on the , which can exacerbate hypoperfusion. For intrinsic renal causes, such as () or , avoidance of nephrotoxic agents like nonsteroidal anti-inflammatory drugs (NSAIDs) and aminoglycosides is critical to prevent further tubular injury and support endogenous repair processes. In cases of glomerulonephritis-associated anuria, immunosuppressive therapy with corticosteroids, such as oral at a dose of 1 mg/kg daily, is administered to reduce inflammation and preserve renal function, often followed by tapering based on response. For severe with persistent anuria and complications like or fluid overload, via dialysis is indicated to bridge the recovery phase, allowing time for tubular epithelial regeneration, which typically occurs over 1-3 weeks. Post-renal anuria due to obstruction requires urgent decompression to prevent irreversible renal damage. Retrograde ureteral stenting or nephrostomy tube placement is performed to restore urine flow, with studies showing comparable efficacy in relieving obstruction from calculi or tumors, though stenting may be preferred in hemodynamically stable patients for its less invasive nature. In (BPH)-related obstruction, (TURP) serves as a definitive intervention, effectively alleviating bladder outlet obstruction and resolving anuria in the majority of cases. Emerging therapies, including mesenchymal stem cell infusions for ischemic ATN, are under investigation in 2025 clinical trials, demonstrating potential to enhance renal repair through and anti-apoptotic effects.

Prognosis

Complications

Untreated or persistent anuria can lead to uremic syndrome, a collection of systemic manifestations resulting from the accumulation of uremic toxins due to severe renal failure. This syndrome includes neurological effects such as uremic encephalopathy, characterized by altered mental status, confusion, and potentially seizures or if severe. Cardiovascular involvement manifests as , an inflammation of the that may cause and effusion, often requiring urgent intervention. Hematological complications encompass platelet dysfunction, leading to increased tendencies through impaired aggregation and despite normal platelet counts. These features typically emerge when creatinine clearance falls below 10-20 mL/min in acute settings, and prompt initiation of dialysis is essential to prevent progression. Cardiovascular complications arise prominently from electrolyte imbalances and volume dysregulation in anuria. Hyperkalemia, due to impaired excretion, frequently induces cardiac arrhythmias, including , which pose immediate life-threatening risks in patients with or anuria. Concurrently, fluid overload from absent urine output contributes to and congestive , exacerbating cardiac strain and independently predicting higher short-term mortality in severe cases. Targeted management, such as dialysis, can mitigate these risks as outlined in supportive care strategies. Infectious complications are heightened in anuric patients, particularly those requiring invasive . Catheter-related urinary tract infections occur in approximately 9-20% of critically ill cases involving indwelling urinary catheters for monitoring or , with incidence rates reaching 8-9 per 1,000 catheter-days. These infections can rapidly progress to , worsening and organ perfusion in the context of underlying renal failure. Prolonged anuria predisposes to multi-organ dysfunction through secondary mechanisms like immobility and buildup. Hepatic dysfunction, marked by elevated transaminases and , arises in up to 25% of associated cases, where muscle breakdown releases proteases that impair liver function. itself may develop from extended or metabolic derangements in persistent anuria, further compounding and leading to or compartment syndromes.

Outcomes

Recovery of renal function in patients with anuria, a severe manifestation of (AKI) stage 3, is influenced heavily by the duration of anuria and promptness of treatment. A duration of anuria exceeding 24 hours predicts incomplete renal recovery with high sensitivity (85%) and moderate specificity (66.7%), whereas earlier intervention within this window supports higher rates of function restoration, often exceeding 60% in responsive cases. Among patients requiring dialysis for anuria, a substantial proportion remain dialysis-dependent and progress to (CKD), particularly if underlying insults persist. In-hospital mortality for anuria as AKI stage 3 ranges from 20% to 50%, reflecting the condition's severity and comorbidities. In intensive care unit settings with multi-organ failure, mortality is particularly high, driven by systemic inflammation and hemodynamic instability. Prognostic factors include advanced age and etiological category. Advanced age increases mortality risk due to reduced physiologic reserve and higher comorbidity burden. Pre-renal causes of anuria, often reversible with fluid resuscitation, generally yield higher recovery rates when addressed promptly, contrasting with lower recovery for intrinsic renal causes involving tubular necrosis. Long-term quality of life is compromised by post-anuria CKD, which elevates cardiovascular event risk 2- to 3-fold within 5 years, encompassing and . This heightened vulnerability underscores the need for ongoing surveillance in survivors.

References

  1. https://my.clevelandclinic.org/health/diseases/21890-anuria
  2. https://www.ncbi.nlm.nih.gov/books/NBK441896/
  3. https://emedicine.medscape.com/article/243492-overview
  4. https://www.healthline.com/health/anuria
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4570603/
  6. https://www.etymonline.com/word/anuria
  7. https://www.merriam-webster.com/dictionary/anuria
  8. https://link.springer.com/chapter/10.1007/978-981-13-7677-1_25
  9. https://www.nlm.nih.gov/medlineplus/ency/article/003425.htm
  10. https://www.pedscases.com/sites/default/files/Pediatric%2520AKI%2520Script.pdf
  11. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30679-1/fulltext
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC6097506/
  13. https://www.osmosis.org/answers/anuria
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC10219694/
  15. https://pubmed.ncbi.nlm.nih.gov/40923578/
  16. https://www.eurekalert.org/news-releases/1104060
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC7121551/
  18. https://www.ncbi.nlm.nih.gov/books/NBK507815/
  19. https://www.ncbi.nlm.nih.gov/books/NBK500032/
  20. https://www.ahajournals.org/doi/10.1161/01.hyp.0000120964.22281.3e
  21. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf
  22. https://www.msdmanuals.com/professional/multimedia/table/staging-criteria-for-acute-kidney-injury-kdigo-2012
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC5094385/
  24. https://kdigo.org/wp-content/uploads/2023/10/KDIGO-AKI-Guideline_Scope-of-Work_25Oct2023_Final.pdf
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC11884078/
  26. https://www.myamericannurse.com/acute-kidney-injury/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC5016271/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC12410291/
  29. https://www.sciencedirect.com/science/article/abs/pii/S0883944123000291
  30. https://www.merckmanuals.com/home/kidney-and-urinary-tract-disorders/kidney-failure/acute-kidney-injury
  31. https://www.ncbi.nlm.nih.gov/books/NBK441859/
  32. https://my.clevelandclinic.org/health/diseases/21509-uremia
  33. https://www.medicalnewstoday.com/articles/320663
  34. https://www.emdocs.net/oliguria-and-anuria-ed-presentations-evaluation-and-management/
  35. https://www.ncbi.nlm.nih.gov/books/NBK560738/
  36. https://www.ncbi.nlm.nih.gov/books/NBK538499/
  37. https://journals.lww.com/esnt/fulltext/2021/21020/a_case_of_factitious_disorder_presenting_as_acute.7.aspx
  38. https://www.amboss.com/us/knowledge/anuria-and-oliguria/
  39. https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-retention/diagnosis
  40. https://www.aafp.org/pubs/afp/issues/2008/0301/p643.html
  41. https://www.aafp.org/pubs/afp/issues/2012/1001/p631.html
  42. https://www.nejm.org/doi/full/10.1056/NEJM199605303342207
  43. https://www.ncbi.nlm.nih.gov/books/NBK542305/
  44. https://www.ccjm.org/content/85/3/231
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2748997/
  46. https://www.medsafe.govt.nz/profs/PUArticles/June2013NSAIDS.htm
  47. https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0673-8
  48. https://www.nature.com/articles/s41581-023-00683-3
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC11743060/
  50. https://indianjnephrol.org/outcomes-of-sepsisassociated-acute-kidney-injury/
  51. https://www.uptodate.com/contents/etiology-and-diagnosis-of-prerenal-disease-and-acute-tubular-necrosis-in-acute-kidney-injury-in-adults
  52. https://emedicine.medscape.com/article/238064-overview
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11747297/
  54. https://www.ncbi.nlm.nih.gov/books/NBK560644/
  55. https://www.wjgnet.com/2220-6124/full/v13/i2/93322.htm
  56. https://www.yalemedicine.org/conditions/enlarged-prostate-benign-prostatic-hyperplasia-bph
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2939444/
  58. https://www.nature.com/articles/s41394-024-00623-8
  59. https://www.uptodate.com/contents/evaluation-of-acute-kidney-injury-among-hospitalized-adult-patients
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC5603084/
  61. https://www.ncbi.nlm.nih.gov/books/NBK507821/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC3061004/
  63. https://www.ncbi.nlm.nih.gov/books/NBK560678/
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC3257513/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC9994307/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10996964/
  67. https://www.ncbi.nlm.nih.gov/books/NBK572135/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC5753426/
  69. https://www.aafp.org/pubs/afp/issues/2019/1201/p687.html
  70. https://emedicine.medscape.com/article/243492-treatment
  71. https://www.espen.org/files/ESPEN-Guidelines/ESPEN-guideline-on-clinical-nutrition-in-hospitalized-patients-with-acute-or-chronic-kidney-disease.pdf
  72. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC11206041/
  74. https://www.ncbi.nlm.nih.gov/books/NBK560884/
  75. https://journals.lww.com/imna/fulltext/2023/03000/mesenchymal_stem_cells_in_the_treatment_of_acute.14.aspx
  76. https://www.ncbi.nlm.nih.gov/books/NBK564327/
  77. https://www.ncbi.nlm.nih.gov/books/NBK536920/
  78. https://emedicine.medscape.com/article/245296-overview
  79. https://onlinelibrary.wiley.com/doi/10.1155/2014/509204
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC8809269/
  81. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0309755
  82. https://www.nature.com/articles/s41598-022-15035-7
  83. https://www.aafp.org/pubs/afp/issues/2002/0301/p907.html
  84. https://www.ncbi.nlm.nih.gov/books/NBK448168/
  85. https://www.kireports.org/article/S2468-0249(19)30037-3/fulltext
  86. https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1645-y
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC11000341/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC10955431/
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC9916069/
  90. https://www.ahajournals.org/doi/10.1161/circulationaha.110.970160
Add your contribution
Related Hubs
User Avatar
No comments yet.